Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19

PHASE3TerminatedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

December 2, 2021

Study Completion Date

December 2, 2021

Conditions
COVID-19
Interventions
DRUG

RO7496998

275 mg tablets

DRUG

Placebo

Matching tablets

Trial Locations (50)

1211

Hôpital Universitaire de Genève (HUG), Geneva

5101

Private Practice Dr Jean Benoit Martinot, Erpent

6200

Maison Médicale La Brèche, Châtelineau

6534

Medif, Gozée

8091

Universitätsspital Zürich, Zurich

9000

Aalborg Universitetshospital, Aalborg

27000

CIMAB SA de CV, Torreón

35100

Ege University Medical Faculty, Izmir

44100

Instituto Jalisciense de Investigacion Clinica S.A. de C.V., Guadalajara

44670

Panamerican Clinical Research S.A de C.V., Guadalajara

49074

CNPE City Clinical Hospital #6 of DCC, Dnipro

50668

Praxis am Ebertplatz, Cologne

61080

Karadeniz Technical University Faculty of Medicine, Trabzon

61124

Municipal Non-profit Enterprise ?City Clinical Hospital #13? of Kharkiv City Council, Kharkiv

61172

Public Non-Profit Enterprise ?City Outpatient Clinic #9? of Kharkiv City Council, Kharkiv

69118

Communal Non-Profit Enterprise City Hospital #7 of Zaporizhzhia City Council, Zaporizhzhia

76230

PanAmerican Clinical Research, Querétaro, Queréaro

235200

County Hospital Caracal, Caracal

550245

Sibiu Emergency Clinical County Hospital, Sibiu

B7602DCK

Instituto Ave Pulmo, Mar del Plata

70200-730

L2 Ip Instituto de Pesquisas Clinicas Ltda ME; Centro Medico Hospitalar, Brasília

72145-450

Chronos Pesquisa Clinica, Taguatinga

80810-040

Hospital Nossa Senhora das Graças, Curitiba

52051-380

Hospital Agamenon Magalhães, Recife

02401-400

Conjunto Hospitalar do Mandaqui, São Paulo

DK-2100

Rigshospitalet Copenhagen University Hospital, Copenhagen

578-0947

Higashiosaka city Medical Center, Higashiosaka-Shi

598-0048

Rinku General Medical Center, Izumisano

252-5188

Sagamihara Kyodo Hospital, Kanagawa

153-0051

Misyuku hospital, Meguro-Ku

286-8520

IUHW Narita Hospital, Narita

831-0016

Houjin Syadan Kouhoukai Takagi Hospital, Okawa-Shi

700-8557

Okayama City Hospital, Okayama

198-0042

Ome Municipal General Hospital, Ome-Shi

591-8555

National Hospital Organization Kinki-Chuo Chest Medical Center, Sakaishi

140-8522

Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai, Shinagawa City

133-0071

Edogawa Medicare Hospital, Tokyo

162-0052

Center Hospital of the National Center for Global Health and Medicine, Tokyo

193-0998

Tokyo Medical University Hachioji Medical Center, Tokyo

06700

Clinstile S.A de C.V., Mexico City

Unknown

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, México

Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1, Vinnytsia

4454-509

Unidade Local de Saude de Matosinhos SA, Matosinhos Municipality

021105

Prof. Dr. Matei Bals Institute of Infectious Diseases, Bucharest

06100

Gazi Universitesi Tip Fakultesi, Ankara

06590

Ankara University Medical Faculty - PPDS, Çankaya

01135

"Medical Center LLC Harmony of Beauty", Kyiv

02091

CNE Kyiv City Clinical Hospital#1 of Exec. Body, Kyiv

03049

Kyiv Railway Clinical Hospital No2 of Branch Health Center of the JSC Ukrainian Rail, Kyiv

04050

Polyclinic of Center of Medical Service and Rehabilitation of State JSHC Artem, Kyiv

Sponsors
All Listed Sponsors
collaborator

Atea Pharmaceuticals, Inc.

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY

NCT04889040 - Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 | Biotech Hunter | Biotech Hunter